ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,459.10
1.11%
US Tech 100
18,514.00
1.00%
Dow Jones
40,589.34
1.64%
Brent Oil
79.745
0.00%
Bitcoin
67,929.08
0.02%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Boundless Bio Inc (BOLD) Quote

Boundless Bio Inc

Boundless Bio Inc (BOLD)

21Shares AG
21Shares AG
3.71
-0.03
(-0.80%)
Closed July 27 4:00PM
Delayed by 15 minutes
3.74
0.03
(0.81%)
After Hours: 7:59PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
3.71
Bid
3.65
Ask
3.99
Volume
104,387
3.62 Day's Range 4.1181
3.39 52 Week Range 15.20
Market Cap
82.564M
Previous Close
3.74
Open
3.78
Last Trade
20
@
3.84
Last Trade Time
Financial Volume
$ 399,034
VWAP
3.8226
Average Volume (3m)
111,801
Shares Outstanding
22,254,537
Dividend Yield
-
PE Ratio
-1.68
Earnings Per Share (EPS)
-2.22
Revenue
-
Net Profit
-49.43M

About Boundless Bio Inc

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical t... Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.boundlessbio.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Boundless Bio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker BOLD. The last closing price for Boundless Bio was $3.74. Over the last year, Boundless Bio shares have traded in a share price range of $ 3.39 to $ 15.20.

Boundless Bio currently has 22,254,537 shares outstanding. The market capitalization of Boundless Bio is $83.23 million. Boundless Bio has a price to earnings ratio (PE ratio) of -1.68.

BOLD Latest News

More News

Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable...

June 05 2024
Business Wire

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 13 2024
Edgar (US Regulatory)

Form 8-K - Current report

May 13 2024
Edgar (US Regulatory)

Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights

BBI-355 Phase 1/2 POTENTIATE clinical trial ongoing; initiated targeted therapy combinations in patients with tumors with EGFR or FGFR oncogene amplifications First patient dosed in Phase 1/2...

May 13 2024
Business Wire

Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable...

May 06 2024
Business Wire

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications

STARMAP (Study Treating Acquired Resistance: MAPK Amplifications) is a first-in-human, 3-part, Phase 1/2 study of BBI-825 as a single agent and in combination with select targeted cancer...

April 11 2024
Business Wire

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

Findings support the ongoing development of BBI-355, a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1) in Phase 1/2 development, as a differentiated treatment approach for...

April 08 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.2787-6.987238950033.98874.433.391131093.62066773CS
4-0.94-20.21505376344.654.7183.391069803.90937485CS
12-5.35-59.05077262699.0612.263.391118016.51308802CS
26-10.54-73.964912280714.2515.23.391428709.16537781CS
52-10.54-73.964912280714.2515.23.391428709.16537781CS
156-10.54-73.964912280714.2515.23.391428709.16537781CS
260-35.22-90.470074492738.93603.3957943045.68037579CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WINTWindtree Therapeutics Inc
$ 8.24
(150.46%)
48.57M
BFIBurgerFi International Inc
$ 0.4206
(97.37%)
313.59M
NBSTWNewbury Street Acquisition Corporation
$ 0.1349
(92.71%)
122.1k
YIBOPlanet Image International Ltd
$ 2.915
(53.43%)
260.07k
CREVCarbon Revolution Public Ltd
$ 9.00
(45.87%)
8.06M
NMHINatures Miracle Holding Inc
$ 0.2035
(-48.06%)
7.69M
TANHTantech Holdings Ltd
$ 0.2585
(-47.23%)
6.75M
DXCMDexCom Inc
$ 64.00
(-40.66%)
53.92M
PSIGPS International Group Ltd
$ 1.42
(-31.40%)
716.26k
POAIPredictive Oncology Inc
$ 1.36
(-27.27%)
6.02M
SLNASelina Hospitality PLC
$ 0.0305
(-18.88%)
408.61M
BFIBurgerFi International Inc
$ 0.4206
(97.37%)
313.59M
NVDANVIDIA Corporation
$ 113.06
(0.69%)
293.33M
SQQQProShares UltraPro Short QQQ
$ 9.10
(-2.88%)
176.49M
SGMOSangamo Therapeutics Inc
$ 0.8612
(28.15%)
123.71M

Discussion

View Full Feed
F4Uvet F4Uvet 2 minutes ago
Still a long way fron Nome through some notoriously unruly water. For those used to coastal waters it might be a formidable challenge. I have been in some water that would make the pirate barge crew wish they were back in the Sacramento delta and the Bering strait is host to some challenging water.
MXSG
janice shell janice shell 3 minutes ago
I'm a couple hours short of 63 and started out in the IT field as well...

Happy Birthday!
BDEZ BDEZ 7 minutes ago
Who runs the @TeamTrump account?

https://x.com/hodgetwins/status/1816635909107835344
ATDS FB CULT ATDS FB CULT 8 minutes ago
So you are saying the elite is divided? Some hold bitcoin, but are stuck with it. So that means, some elite got fooled into crypto.

While real brokers (or elite) are avoiding crypto.

So where do the 'real' elite stand on crypto. Because all major banks and financia
BTCUSD
Jimmy Joe Jimmy Joe 13 minutes ago
I mean is it hard to find a company that is profitable, or are we captives of $DBMM........

He knows exactly what is going on and only pretends when he makes lame arguments against $DBMM.

Funny thing is how he understands the litigation in NetList cases yet can't seem
DBMM
sharky sharky 14 minutes ago
9-1 buys vs sells on Friday. Accumulation picking up

$BLEG
BLEG
janice shell janice shell 15 minutes ago
LOLOLOLOL!!

Was writing a reply to your PM, but IHub PMs are down for maintenance. So I'll just post it here. Don't let the fascist moderators and admins know!!

Jesus. They're threatened by EVERYTHING. They want to be allowed to explore posters' "motivations". WTF? Ho
Murphydog25 Murphydog25 19 minutes ago
Your missing the point she's been back on X in the last 2 hours to answer no to RS but won't answer my and another persons questions about CIVET USA 🤷‍♂️ I can't find any information about it nor can you 🤷‍♂️
NWPN
noradio noradio 20 minutes ago
He has 600 posts on this board, you have 6000... Perhaps it is you who should be moving on.🤔
ERHE
jeunke22 jeunke22 21 minutes ago
Renewal of shelf offering to 100 Mio makes all business sense. Company has great cash ( until deep into 2025) position, has been very frugal in tapping funds from existing, running shelf from Roth and LPC. Both sources together could still provide around 40-45 mio under the ‘ old’ shelf and …
LWLG
spdpro spdpro 26 minutes ago
another good btc chart > and other stuff
https://www.centralcharts.com/en/charts/6863-btc-usd
https://www.centralcharts.com/en/charts/8595-nasdaq-composite
rockhunter rockhunter 27 minutes ago
Crazy to think that no one on here has even had no thoughts that if this oportunity is real... that there is actual millions... possibly billions... of dollars within our reach... that this could just be fun money for these new operators. Toying you all for a bit... stealing your shares.. running yo
HIRU
Welcome2Pinkyland Welcome2Pinkyland 28 minutes ago
For sure- superior grammar skills and the queen of the Ihub fraud team. The total package.
Truth and Transparency Truth and Transparency 28 minutes ago
Unfortunately, the amazing businessman that we believed Mr. Mark Smith to be is revealing himself to be the Mr. Bean of businessmen
NB
tmcfo tmcfo 29 minutes ago
You the man Adjusted! I hope they are nice enough to let you in as a major shareholder..buying more next week
MVNT
StocktonCA StocktonCA 30 minutes ago
very intrigueing, they added shares bc the purchaser knew the value will increase once significant trials have been completed. this company is way undervalued. big players in the know have loaded the boat bc they are aware of the exponential increase in bound.
GLTA longs who stayed on the bul
RSPI
BDEZ BDEZ 31 minutes ago
Thoughts? https://x.com/its_The_Dr/status/1816638114820972750
janice shell janice shell 32 minutes ago
❌️ is killing it....wouldn't it be sensible for us to give them a decent run for their money...we have the infrastructure and staff to do it

Srsly?? X is funded by one of the richest men in the world. IHub was created as a site to service penny plungers. It was initially quite succes
fuagf fuagf 33 minutes ago
Yep, knew that was your point.

2:34pm here. Enough. Cheers.
fuagf fuagf 34 minutes ago
Forever t'will be. Years ago something clicked for me, if an organization had a word like "freedom"
or "liberty" in it's name then watch out baby, it ain't good for but a relative wealthy few.

"There we go with the secretive opposite meaning group names. Again."
Nezitic Nezitic 35 minutes ago
Lol
PSRU
lakers17 lakers17 37 minutes ago
It’s a historic week for the cryptocurrency markets with spot ether exchange-traded funds making their debut.

Franklin Templeton is one of the nine spot ether ETF applicants which got approval Tuesday from the Securities and Exchange commission.

The firm is behind the F
The Night Stalker The Night Stalker 38 minutes ago
STAL big history of runs
STAL
Acme Investments Acme Investments 39 minutes ago
Well let's throw Tim Sykes into the conversation while we're at it!! Sell courses get rich, actually trade 99% fail!!
HIRU

Your Recent History

NASDAQ
BOLD
Boundless Bio
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved